Patient case: 52-year-old male with Colon cancer. Genetic variant: KRAS (G13D), BRAF (V600E). Other conditions: Type II Diabetes, Hypertension.

Clinical trial: Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Summary: RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
  PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine when given together with oxaliplatin and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer that cannot be removed by surgery.

Detailed description: OBJECTIVES:
  Primary
  -  Determine the maximum tolerated dose and recommended phase II dose of capecitabine administered in combination with oxaliplatin and irinotecan in patients with unresectable advanced or metastatic colorectal cancer. (Phase I)
  -  Determine the efficacy of this regimen in these patients. (Phase II)
  Secondary
  -  Determine the tolerability of this regimen in these patients. (Phase II)
  OUTLINE: This is a multicenter, phase I dose-escalation study of capecitabine followed by a phase II study.
  -  Phase I: Patients receive oxaliplatin IV over 2 hours on days 1 and 15, irinotecan IV over 1 hour on days 8 and 22, and oral capecitabine twice daily on days 1-29. Treatment repeats every 5 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
  -  Phase II: Patients receive capecitabine at the MTD and irinotecan and oxaliplatin as in phase I.
  After completion of study treatment, patients are followed every 2 months for 1 year and then every 4 months thereafter.
  PROJECTED ACCRUAL: A total of 23-32 patients (3-12 for the phase I portion and 20 for the phase II portion) will be accrued for this study within 2.75 years

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically or cytologically confirmed unresectable advanced or metastatic colorectal cancer
  -  Measurable disease (phase II only)
  -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan or MRI
  -  No presence or history of CNS metastases
  PATIENT CHARACTERISTICS:
  Age
  -  18 to 70
  Performance status
  -  WHO 0-1
  Life expectancy
  -  Not specified
  Hematopoietic
  -  Absolute neutrophil count ≥ 1,500/mm^3
  -  Platelet count ≥ 100,000/mm^3
  Hepatic
  -  Bilirubin ≤ 1.25 times upper limit of normal (ULN) (1.5 times ULN if liver metastases are present)
  -  AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present)
  Renal
  -  Creatinine clearance > 60 mL/min
  Cardiovascular
  -  No New York Heart Association class III-IV congestive heart failure
  -  No symptomatic coronary artery disease
  -  No uncontrolled cardiac arrhythmia
  -  No myocardial infarction within the past year
  -  No other clinically significant cardiac disease
  Immunologic
  -  No active autoimmune disease
  -  No uncontrolled infection
  -  No prior severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluorouracil
  -  No known hypersensitivity to any component of study drugs
  Other
  -  Not pregnant or nursing
  -  Negative pregnancy test
  -  Patients must use effective contraception during and for 1 year after study participation
  -  No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer
  -  No peripheral neuropathy > grade 1 of any origin (e.g., alcohol or diabetes)
  -  No nausea, vomiting, or malabsorption syndrome that would preclude ingestion or absorption of oral medication
  -  No psychiatric disability that would preclude study compliance
  -  No uncontrolled diabetes
  -  No other serious underlying medical condition that would preclude study participation
  -  No known dihydropyrimidine dehydrogenase deficiency
  PRIOR CONCURRENT THERAPY:
  Biologic therapy
  -  No concurrent prophylactic hematopoietic growth factors
  Chemotherapy
  -  More than 6 months since prior adjuvant fluoropyrimidine chemotherapy
  -  No other prior chemotherapy
  Endocrine therapy
  -  Not specified
  Radiotherapy
  -  No concurrent radiotherapy
  -  Concurrent radiotherapy of a single painful lesion allowed
  Surgery
  -  Not specified
  Other
  -  More than 30 days since prior clinical trial participation
  -  No other concurrent experimental drugs
  -  No other concurrent anticancer therapy
  -  No concurrent sorivudine or its chemically-related analogues (e.g., lamivudine)

Relevance to patient case: not relevant